UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended November 30, 2011.
or
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 0-17988
Neogen Corporation
(Exact name of registrant as specified in its charter)
Michigan | 38-2367843 | |
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification Number) |
620 Lesher Place
Lansing, Michigan 48912
(Address of principal executive offices, including zip code)
(517) 372-9200
(Registrants telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (see definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act):
Large accelerated filer | x | Accelerated filer | ¨ | |||
Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller Reporting Company | ¨ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):
YES ¨ NO x
As of December 1, 2011, there were 23,526,643 shares of Common Stock outstanding.
NEOGEN CORPORATION AND SUBSIDIARIES
1
PART I FINANCIAL INFORMATION
Item 1. | Interim Consolidated Financial Statements |
NEOGEN CORPORATION AND SUBSIDIARIES
November 30, | May 31, | |||||||
2011 | 2011 | |||||||
(In thousands, except share and per share amounts) |
||||||||
(Unaudited) | (Audited) | |||||||
ASSETS |
||||||||
CURRENT ASSETS |
||||||||
Cash and cash equivalents |
$ | 36,972 | $ | 35,844 | ||||
Marketable securities |
18,634 | 20,239 | ||||||
Accounts receivable, less allowance of $800 and $800 |
31,869 | 28,634 | ||||||
Inventories |
36,425 | 31,994 | ||||||
Deferred income taxes |
1,044 | 1,044 | ||||||
Prepaid expenses and other current assets |
5,474 | 4,747 | ||||||
|
|
|
|
|||||
TOTAL CURRENT ASSETS |
130,418 | 122,502 | ||||||
NET PROPERTY AND EQUIPMENT |
28,888 | 22,340 | ||||||
OTHER ASSETS |
||||||||
Goodwill |
51,634 | 51,584 | ||||||
Other non-amortizable intangible assets |
5,166 | 5,166 | ||||||
Customer based intangibles, net of accumulated amortization of $6,241 and $5,431 |
11,196 | 12,006 | ||||||
Other non-current assets, net of accumulated amortization of $3,152 and $2,789 |
7,016 | 6,064 | ||||||
|
|
|
|
|||||
75,012 | 74,820 | |||||||
|
|
|
|
|||||
TOTAL ASSETS |
$ | 234,318 | $ | 219,662 | ||||
|
|
|
|
|||||
LIABILITIES AND EQUITY |
||||||||
CURRENT LIABILITIES |
||||||||
Accounts payable |
$ | 9,611 | $ | 8,516 | ||||
Accrued compensation |
2,536 | 2,715 | ||||||
Income taxes |
1,588 | 0 | ||||||
Other accruals |
4,674 | 6,566 | ||||||
|
|
|
|
|||||
TOTAL CURRENT LIABILITIES |
18,409 | 17,797 | ||||||
DEFERRED INCOME TAXES |
8,347 | 8,347 | ||||||
OTHER LONG-TERM LIABILITIES |
4,436 | 4,540 | ||||||
|
|
|
|
|||||
12,783 | 12,887 | |||||||
|
|
|
|
|||||
TOTAL LIABILITIES |
31,192 | 30,684 | ||||||
EQUITY |
||||||||
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding |
0 | 0 | ||||||
Common stock, $.16 par value, 60,000,000 shares authorized, 23,526,643 and 23,290,604 shares issued and outstanding at November 30, 2011 and May 31, 2011, respectively |
3,764 | 3,727 | ||||||
Additional paid-in capital |
84,794 | 81,248 | ||||||
Accumulated other comprehensive loss |
(1,070 | ) | (394 | ) | ||||
Retained earnings |
115,312 | 104,064 | ||||||
|
|
|
|
|||||
Total Neogen Corporation Stockholders Equity |
202,800 | 188,645 | ||||||
Noncontrolling interest |
326 | 333 | ||||||
|
|
|
|
|||||
TOTAL EQUITY |
203,126 | 188,978 | ||||||
|
|
|
|
|||||
TOTAL LIABILITIES AND EQUITY |
$ | 234,318 | $ | 219,662 | ||||
|
|
|
|
See notes to interim consolidated financial statements
2
NEOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
Three Months Ended November 30 |
Six Months Ended November 30 |
|||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||
Net sales |
$ | 44,891 | $ | 43,931 | $ | 90,588 | $ | 86,853 | ||||||||
Cost of goods sold |
22,234 | 21,443 | 44,954 | 41,598 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
GROSS MARGIN |
22,657 | 22,488 | 45,634 | 45,255 | ||||||||||||
OPERATING EXPENSES |
||||||||||||||||
Sales and marketing |
8,631 | 7,504 | 16,734 | 15,016 | ||||||||||||
General and administrative |
4,173 | 3,714 | 8,185 | 7,576 | ||||||||||||
Research and development |
1,710 | 1,641 | 3,221 | 3,438 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
14,514 | 12,859 | 28,140 | 26,030 | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||
OPERATING INCOME |
8,143 | 9,629 | 17,494 | 19,225 | ||||||||||||
OTHER INCOME (EXPENSE) |
||||||||||||||||
Interest income |
26 | 28 | 48 | 57 | ||||||||||||
Change in purchase consideration |
| (100 | ) | | (400 | ) | ||||||||||
Other income (expense) |
(32 | ) | (47 | ) | (101 | ) | (147 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
(6 | ) | (119 | ) | (53 | ) | (490 | ) | |||||||||
|
|
|
|
|
|
|
|
|||||||||
INCOME BEFORE INCOME TAXES |
8,137 | 9,510 | 17,441 | 18,735 | ||||||||||||
INCOME TAXES |
2,900 | 3,400 | 6,200 | 6,800 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
NET INCOME |
5,237 | 6,110 | $ | 11,241 | $ | 11,935 | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
NET INCOME PER SHARE |
||||||||||||||||
Basic |
$ | 0.22 | $ | 0.27 | $ | 0.48 | $ | 0.52 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Diluted |
$ | 0.22 | $ | 0.26 | $ | 0.47 | $ | 0.51 | ||||||||
|
|
|
|
|
|
|
|
See notes to interim consolidated financial statements
3
NEOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF EQUITY (UNAUDITED)
Common Stock | Additional Paid-in Capital |
Accumulated Other Comprehensive Income (Loss) |
Retained Earnings |
Noncontrolling Interest |
Total | |||||||||||||||||||||||
Shares | Amount | |||||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||||||
Balance, June 1, 2011 |
23,291 | $ | 3,727 | $ | 81,248 | $ | (394 | ) | $ | 104,064 | $ | 333 | $ | 188,978 | ||||||||||||||
Issuance of shares of common stock under equity compensation plans, and share based compensation, including $1,364 of excess income tax benefit |
229 | 36 | 3,325 | 3,361 | ||||||||||||||||||||||||
Issuance of shares under employee stock purchase plan |
6 | 1 | 221 | 222 | ||||||||||||||||||||||||
Comprehensive income: |
||||||||||||||||||||||||||||
Net income (loss) for the six months ended November 30, 2011 |
11,248 | (7 | ) | 11,241 | ||||||||||||||||||||||||
Foreign currency translation adjustments |
(676 | ) | (676 | ) | ||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||
Total comprehensive income ($12,794 in the six months ended November 30, 2010) |
10,565 | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, November 30, 2011 |
23,526 | $ | 3,764 | $ | 84,794 | $ | (1,070 | ) | $ | 115,312 | $ | 326 | $ | 203,126 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to interim consolidated financial statements
4
NEOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Six Months Ended | ||||||||
November 30, | ||||||||
2011 | 2010 | |||||||
(In thousands) | ||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
Net income |
$ | 11,241 | $ | 11,935 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
2,911 | 2,584 | ||||||
Share based compensation |
1,072 | 1,240 | ||||||
Excess income tax benefit from the exercise of stock options |
(1,364 | ) | (322 | ) | ||||
Changes in operating assets and liabilities, net of business acquisitions: |
||||||||
Accounts receivable |
(3,235 | ) | (215 | ) | ||||
Inventories |
(4,411 | ) | 213 | |||||
Prepaid expenses and other current assets |
(726 | ) | 292 | |||||
Accounts payable, accruals and other |
686 | 3,832 | ||||||
|
|
|
|
|||||
NET CASH PROVIDED BY OPERATING ACTIVITIES |
6,174 | 19,559 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
Purchases of property and equipment and other assets |
(8,897 | ) | (3,423 | ) | ||||
Proceeds from the sale of marketable securities |
39,804 | 13,034 | ||||||
Purchases of marketable securities |
(38,199 | ) | (30,345 | ) | ||||
Payments for business acquisitions |
(813 | ) | 0 | |||||
|
|
|
|
|||||
NET CASH USED IN INVESTING ACTIVITIES |
(8,105 | ) | (20,734 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
Increase (decrease) in other long-term liabilities |
(854 | ) | 257 | |||||
Net proceeds from issuance of common stock |
2,511 | 4,871 | ||||||
Excess income tax benefit from the exercise of stock options |
1,364 | 322 | ||||||
|
|
|
|
|||||
NET CASH PROVIDED BY FINANCING ACTIVITIES |
3,021 | 5,450 | ||||||
EFFECT OF EXCHANGE RATE ON CASH |
38 | 0 | ||||||
INCREASE IN CASH |
1,128 | 4,275 | ||||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD |
35,844 | 22,806 | ||||||
|
|
|
|
|||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
$ | 36,972 | $ | 27,081 | ||||
|
|
|
|
See notes to interim consolidated financial statements
5
NEOGEN CORPORATION AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the six month period ended November 30, 2011 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2012. For more complete financial information, these consolidated financial statements should be read in conjunction with the May 31, 2011 audited consolidated financial statements and the notes thereto included in the Companys annual report on Form 10-K for the year ended May 31, 2011.
2. INVENTORIES
Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories follow:
November 30, 2011 |
May 31, 2011 |
|||||||
(In thousands) | ||||||||
Raw materials |
$ | 15,475 | $ | 12,125 | ||||
Work-in-process |
2,718 | 2,192 | ||||||
Finished and purchased goods |
18,232 | 17,677 | ||||||
|
|
|
|
|||||
$ | 36,425 | $ | 31,994 | |||||
|
|
|
|
3. NET INCOME PER SHARE
The calculation of net income per share follows:
Three Months Ended November 30, |
Six Months Ended November 30, |
|||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Numerator for basic and diluted net income per share: |
||||||||||||||||
Net income |
$ | 5,237 | $ | 6,110 | $ | 11,241 | $ | 11,935 | ||||||||
Denominator: |
||||||||||||||||
Denominator for basic net income per share: |
||||||||||||||||
Weighted average shares |
23,418 | 22,926 | 23,369 | 22,802 | ||||||||||||
Effect of dilutive stock options and warrants |
556 | 803 | 632 | 797 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Denominator for diluted net income per share |
23,974 | 23,729 | 24,001 | 23,599 | ||||||||||||
Net income per share: |
||||||||||||||||
Basic |
$ | 0.22 | $ | 0.27 | $ | 0.48 | $ | 0.52 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Diluted |
$ | 0.22 | $ | 0.26 | $ | 0.47 | $ | 0.51 | ||||||||
|
|
|
|
|
|
|
|
6
4. SEGMENT INFORMATION
The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including a complete line of consumable products marketed to veterinarians and animal health product distributors; the segment also provides genetic identification services. Additionally, Animal Safety produces and markets rodenticides and disinfectants to assist in control of rodents and disease in and around agricultural, food production and other facilities.
Segment information for the three months ended November 30, 2011 and 2010 follows:
Food Safety |
Animal Safety |
Corporate and Eliminations (1) |
Total | |||||||||||||
(In thousands) | ||||||||||||||||
Fiscal 2012 |
||||||||||||||||
Net sales to external customers |
$ | 22,042 | $ | 22,849 | $ | 0 | $ | 44,891 | ||||||||
Operating income (reduction) |
5,679 | 2,933 | (469 | ) | 8,143 | |||||||||||
Total assets |
84,719 | 101,341 | 48,258 | 234,318 | ||||||||||||
Fiscal 2011 |
||||||||||||||||
Net sales to external customers |
$ | 21,341 | $ | 22,590 | $ | 0 | $ | 43,931 | ||||||||
Operating income (reduction) |
6,264 | 3,775 | (410 | ) | 9,629 | |||||||||||
Total assets |
76,790 | 87,914 | 38,971 | 203,675 |
Segment information for the six months ended November 30, 2011 and 2010 follows:
Food Safety |
Animal Safety |
Corporate and Eliminations (1) |
Total | |||||||||||||
(In thousands) | ||||||||||||||||
Fiscal 2012 |
||||||||||||||||
Net sales to external customers |
$ | 45,324 | $ | 45,264 | $ | 0 | $ | 90,588 | ||||||||
Operating income (reduction) |
12,843 | 5,676 | (1,025 | ) | 17,494 | |||||||||||
Fiscal 2011 |
||||||||||||||||
Net sales to external customers |
$ | 43,593 | $ | 43,260 | $ | 0 | $ | 86,853 | ||||||||
Operating income (reduction) |
13,237 | 6,886 | (898 | ) | 19,225 |
(1) | Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, deferred assets and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions. |
7
5. EQUITY COMPENSATION PLANS
Options are generally granted under the employee and director stock option plan for 5 year periods and become exercisable in equal annual installments during that period. Certain non-qualified options are granted for 10 year periods. A summary of stock option activity during the six months ended November 30, 2011 follows:
Shares | Weighted-Average Exercise Price |
|||||||
Options outstanding at June 1, 2011 |
1,574,000 | $ | 17.77 | |||||
Granted |
313,000 | 34.60 | ||||||
Exercised |
(229,000 | ) | 11.59 | |||||
Forfeited |
(31,000 | ) | 14.88 | |||||
|
|
|||||||
Options outstanding at November 30, 2011 |
1,627,000 | 21.94 |
During the three and six month periods ended November 30, 2011 and 2010, the Company recorded $472,000 and $564,000 and $1,072,000 and $1,240,000, respectively, of compensation expense related to its share-based awards.
The weighted-average fair value of stock options granted during FY-2012 and 2011, estimated on the date of grant using the Black-Scholes option pricing model was $10.42 and $8.60 respectively, per option. The fair value of stock options granted was estimated using the following weighted-average assumptions.
FY-12 | FY-11 | |||||||
Risk-free interest rate |
1.17 | % | 1.7 | % | ||||
Expected dividend yield |
0 | % | 0 | % | ||||
Expected stock price volatility |
36.4 | % | 35.8 | % | ||||
Expected option life |
4.0 years | 4.0 years |
The Company has an Employee Stock Purchase plan that provides for employee stock purchases at a 5% discount to market price. The discount is expensed as of the date of purchase.
6. NEW ACCOUNTING PRONOUNCEMENTS
In June 2011, the FASB issued an accounting standards update titled Presentation of Comprehensive Income. This update eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. An entity can elect to present items of net income and other comprehensive income in one continuous statement or in two separate consecutive statements. Each component of net income and each component of other comprehensive income, together with totals for comprehensive income and its two parts, net income and other comprehensive income, must be displayed under either alternative. The new disclosure requirements are effective for fiscal years beginning after December 15, 2011.
In September 2011, the FASB issued an accounting standards update titled Intangibles Goodwill and Other: Testing Goodwill for Impairment. This update gives the option of performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount and, in some cases, skip the two-step impairment test. This standard is effective for fiscal years beginning after December 15, 2011, and early adoption is permitted.
The above ASUs issued by the FASB, upon adoption, are not expected by management to have a material effect on the Companys consolidated financial statements.
8
7. BUSINESS AND PRODUCT LINE ACQUISITIONS
On April 1, 2010, Neogen Corporation acquired GeneSeek, Inc. of Lincoln, Nebraska, a leading commercial agricultural genetic laboratory. GeneSeeks technology employs high-resolution DNA genotyping for identity and trait analysis in a variety of important animal and agricultural plant species. Consideration for the purchase was $14,050,000 in cash and secondary payment obligations of up to $7,000,000. The allocation of the purchase price included accounts receivable of $1,923,000, inventory of $1,512,000, fixed assets of $847,000, current liabilities of $905,000, deferred tax liabilities of $2,530,000, secondary payment liabilities of $3,583,000, and the remainder to goodwill (not deductible for tax purposes) and other intangible assets (with estimated lives of 5-20 years). The allocation was generally based on the fair value of these assets determined using the income approach. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. The secondary payment was based upon future operating results of the GeneSeek business through 2013, and payable annually over a three year period, measured at fair value, and is considered a Level 3 fair value measurement. The Company recorded a charge within other income (expense) of approximately $787,000 for the year ended May 31, 2011, representing the increase from its original estimate in fair value of the secondary payment liability. As of May 31, 2011, the balance of the secondary payment liability recorded was approximately $4,370,000. A payment of $1,856,000 was made in June, 2011 to the former owners of GeneSeek, comprised of $1,537,000 for the first year contingent payment and an additional $319,000 for inventory purchased post acquisition and settlement of other liabilities. The acquisition has been integrated into the Animal Safety segment.
On June 21, 2011, Neogen Corporation acquired the assets of VeroMara seafood testing laboratory for approximately $813,000 in cash and a potential secondary payment of approximately $200,000 from its parent company, GlycoMar Ltd. Based in Oban, Scotland, VeroMara offers testing services to the shellfish and salmon aquaculture industries. VeroMaras services include testing for shellfish toxins, general foodborne pathogens, including E. coli , noroviruses, and salmon husbandry. VeroMara recorded revenues of approximately $800,000 (U.S.) in its most recently completed fiscal year. The purchase accounting for this transaction will be completed in fiscal year 2012. The acquisition is expected to provide a strong synergistic fit for the Companys Food Safety segment.
8. LONG TERM DEBT AND LIABILITIES
The Company has a financing agreement in place with a bank (no amounts drawn at November 30, 2011 or May 31, 2011) which, through the first quarter of fiscal 2011, provided for an unsecured revolving line of credit of $10,000,000. Effective August 31, 2011, the Company extended the agreement by one year through November 30, 2013 and increased the total available credit to $12,000,000. The incremental credit is to provide for flexibility for potential foreign currency hedging strategies. The interest rate is at LIBOR plus 100 basis points (rate under terms of the agreement was 1.26% at November 30, 2011). Financial covenants include maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the Company was in compliance with at November 30, 2011.
9. COMMITMENTS AND CONTINGENCIES
The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company is currently expensing annual costs of remediation, which have ranged from $50,000 to $105,000 per year over the past five years. The Companys estimated liability for these costs of $916,000 at November 30, 2011 and 2010, measured on an undiscounted basis over an estimated period of 15 years, is recorded within other long term liabilities in the consolidated balance sheet.
The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, will not have a material effect on its future results of operations or financial position.
10. STOCK PURCHASE
In December 2008, the Companys Board of Directors authorized a program to purchase, subject to market conditions, up to 750,000 shares of the Companys common stock. As of November 30, 2011, 74,684 cumulative shares had been purchased in negotiated and open market transactions for a total price, including commissions, of approximately $923,000. Shares purchased under the program were retired. There have been no purchases in fiscal year 2012 and there were none in 2011.
9
Item 2. | Managements Discussion and Analysis of Financial Conditions and Results of Operations |
The information in this Managements Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future performance. While management is optimistic about the Companys long-term prospects, historical financial information may not be indicative of future financial performance.
Safe Harbor and Forward-Looking Statements
Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the foregoing, the words believes, anticipates, plans, expects, seeks, estimates, and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Companys reports on file at the Securities and Exchange Commission, that could cause Neogen Corporations results to differ materially from those indicated by such forward-looking statements, including those detailed in this Managements Discussion and Analysis of Financial Condition and Results of Operations.
In addition, any forward-looking statements represent managements views only as of the day this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing managements views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.
Critical Accounting Policies and Estimates
The discussion and analysis of the Companys financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including those related to receivable allowances, inventories, accruals and intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no material changes to the critical accounting policies and estimates disclosed in the Companys Annual Report on Form 10-K for the fiscal year ended May 31, 2011.
10
Results of Operations
Executive Overview
Neogen Corporation revenues increased by 2.2% in the second quarter to $44.9 million and by 4.3% to $90.6 million for the six-month period ended November 30, 2011 each, when compared to the prior year. Food Safety revenues increased by 3.3% and 4.0% in the quarter and the six-month period ended November 30, 2011, respectively. Animal Safety revenues increased by 1.1% and 4.6% in the quarter and in the six-month period ended November 30, 2011, respectively. Exclusive of the revenues from the VeroMara acquisition, which was made in June 2011, Food Safety revenue increases were 2.8% and 3.4% in the second quarter and year-to-date periods, respectively. Gross margins decreased from 51.2% in the November 2010 quarter to 50.5% in the November 2011 quarter and decreased from 52.1% to 50.4% on a year-to-date basis. The change in margin percentage for the year to date period is primarily the result of shifts in product mix and increases in fixed manufacturing cost. Operating margins decreased in the comparative quarter and six-month periods from 21.9% to 18.1% and from 22.1% to 19.3%, respectively. The decreases were primarily the result of investments in sales and customer support personnel and infrastructure, part of a long-term strategy that management believes may result in revenue gains and efficiencies in the future.
Revenues
Three and six months ended November 30, 2011 compared to three and six months ended November 30, 2010:
Three Months Ended November 30, | ||||||||||||||||
2011 | 2010 | Increase / (Decrease) |
% | |||||||||||||
(In thousands except percents) | ||||||||||||||||
Food Safety |
||||||||||||||||
Natural Toxins, Allergens & Drug Residues |
$ | 11,501 | $ | 11,192 | $ | 309 | 2.8 | |||||||||
Bacteria & General Sanitation |
5,839 | 5,393 | 446 | 8.3 | ||||||||||||
Dehydrated Culture Media & Other |
4,702 | 4,756 | (54 | ) | (1.1 | ) | ||||||||||
|
|
|
|
|
|
|||||||||||
$ | 22,042 | $ | 21,341 | 701 | 3.3 | |||||||||||
Animal Safety |
||||||||||||||||
Life Science & Other |
1,974 | 1,883 | 91 | 4.8 | ||||||||||||
Vaccines |
852 | 746 | 106 | 14.2 | ||||||||||||
Rodenticides & Disinfectants |
7,106 | 7,868 | (762 | ) | (9.7 | ) | ||||||||||
Veterinary Instruments & Other |
8,986 | 7,484 | 1,502 | 20.1 | ||||||||||||
DNA Testing |
3,931 | 4,609 | (678 | ) | (14.7 | ) | ||||||||||
|
|
|
|
|
|
|||||||||||
22,849 | 22,590 | 259 | 1.1 | |||||||||||||
|
|
|
|
|
|
|||||||||||
Total Revenues |
$ | 44,891 | $ | 43,931 | $ | 960 | 2.2 | |||||||||
|
|
|
|
|
|
Six Months Ended November 30, | ||||||||||||||||
2011 | 2010 | Increase / (Decrease) |
% | |||||||||||||
(In thousands except percents) | ||||||||||||||||
Food Safety |
||||||||||||||||
Natural Toxins, Allergens & Drug Residues |
$ | 23,463 | $ | 22,671 | $ | 792 | 3.5 | |||||||||
Bacteria & General Sanitation |
12,274 | 10,743 | 1,531 | 14.3 | ||||||||||||
Dehydrated Culture Media & Other |
9,587 | 10,179 | (592 | ) | (5.8 | ) | ||||||||||
|
|
|
|
|
|
|||||||||||
$ | 45,324 | $ | 43,593 | 1,731 | 4.0 | |||||||||||
Animal Safety |
||||||||||||||||
Life Science & Other |
4,071 | 3,953 | 118 | 3.0 | ||||||||||||
Vaccines |
1,339 | 1,328 | 11 | 0.8 | ||||||||||||
Rodenticides & Disinfectants |
13,730 | 13,561 | 169 | 1.2 | ||||||||||||
Veterinary Instruments & Other |
18,427 | 15,069 | 3,358 | 22.3 | ||||||||||||
DNA Testing |
7,697 | 9,349 | (1,652 | ) | (17.7 | ) | ||||||||||
|
|
|
|
|
|
|||||||||||
45,264 | 43,260 | 2,004 | 4.6 | |||||||||||||
|
|
|
|
|
|
|||||||||||
Total Revenues |
$ | 90,588 | $ | 86,853 | $ | 3,735 | 4.3 | |||||||||
|
|
|
|
|
|
11
Food Safety revenues increased 3.3% in the second quarter and 4.0% in the first six months of FY-12, each compared to the prior year. Exclusive of the VeroMara acquisition, revenues increased by 2.8% and 3.4% in the quarter and six month periods, in comparison to the same periods of the prior year. Sales of Natural Toxin, Allergen and Drug Residue products increased by 2.8% in the quarter and by 3.5% for the year-to-date in comparison with FY-11. Within this product group, BetaStar Kits to detect drug residues increased by 7.5% in the second quarter and by 17.0% for the first six months of the fiscal year. Mycotoxin second quarter revenues declined by 0.9%, and by 5.8% for the six- month period as there were fewer incidences of Aflatoxin and DON outbreaks during the summer and fall harvest season. Revenues from Food Allergen tests increased 2.1% in the second quarter and 1.1% for the six months ended November 2011. Bacteria and General Sanitation product revenues increased by 8.3% in the quarter and 14.3% for the first six months of FY-12 compared to FY-11 primarily due to placements of Soleris ® optical microbial detection systems in the current year. Dehydrated Culture Media and Other product revenues decreased by 1.1% and 5.8% in the quarter and in the six-month periods, respectively, primarily due to the loss of a significant customer due to credit issues and the closure of a plant by another significant customer.
Animal Safety revenues increased by 1.1% in the second quarter and 4.6% for the year to date period ended November 30, 2011 in comparison with the prior year. Life sciences and other revenue increased by 4.8% in the quarter and 3.0% in the six month periods, respectively. Forensic test kit revenues were up 12% in the second quarter compared with the prior year quarter and the launch of an improved substrate product led to an increase in sales of test reagents that Neogen offers to other test kit manufacturers. Vaccine revenues increased by 14.2% for the second quarter and increased by 0.8% in the first six months of FY-12, due to timing of orders and the shipment of product to large key distributors. Rodenticide and Disinfectant product revenues decreased by 9.7% in the second quarter but increased by 1.2% on a year-to-date basis. Rodenticides declined due to strong 4th quarter FY-2011 sales ahead of a June 2011 change in EPA rules regarding labeling of these products. The strong fourth quarter sales led to lower first and second quarter FY-2012 revenues. Sales of cleaners and disinfectants have increased in the comparative three and six months periods due to sales to international distributors. Veterinary Instrument and other product revenues increased by 20.1% and 22.3% in the quarter and six months, respectively, in comparison with the prior year. Increases were due to strong detectable needle revenues and significant sales increases in companion animal products, veterinary gloves and apparel products sold through key veterinary distribution channels. Revenues decreased at GeneSeek by 14.7% and 17.7% for the three months and six months ended November 30, 2011 compared to the same periods in the prior year, due primarily to business from new products and contracts earned in the prior year which were not achieved to the same extent, or did not occur, during the first half of FY2012. GeneSeeks contract business is not necessarily predictable from period-to-period as to its timing or amount.
Gross margins decreased from 51.2% in the second quarter of FY-11 to 50.5% in the second quarter of FY-12, and from 52.1% in the first six months of FY-2011 to 50.4% in the same period of FY-12. This resulted principally from changes in product mix and increased manufacturing expenses.
Operating margins decreased from 21.9% to 18.1% in the second quarter and from 22.1% to 19.3% in the first six months of FY-12 as compared to the first six months of FY-11. Sales and marketing expenses as expressed as a percentage of revenues increased from 17.1% to 19.2% in the second quarter and increased from 17.3% to 18.5% on a year-to-date basis. The increase in sales and marketing expenses is the direct effect of additional sales, marketing and customer service representatives added during the year. These positions were added to help the company capture and support available market opportunities. General and administrative expenses increased from 8.5% to 9.3% of revenues in the second quarter, and from 8.7% to 9.0% on a year to date basis. The change in general and administrative expense is due to the increased compensation costs, amortization from acquired businesses, and costs associated with increased governmental licensing and regulatory affairs. Research expense increased from 3.7% to 3.8% in the second quarter and decreased from 4.0% to 3.6% in the first six months of FY-12. While these expenses vary on a quarter to quarter basis depending on the timing of new projects and the completion of existing projects, management expects that research and development efforts will range between 4% to 5% in support of existing products and for development of future products.
Financial Condition and Liquidity
The overall cash and marketable securities position of the company was $55,606,000 at November 30, 2011, compared to $56,083,000 at May 31, 2011. Approximately $6,174,000 in cash was generated from operations during the six months ended November 30, 2011. Net cash proceeds of $2,511,000 were realized from the exercise of stock options and issuance of shares under the Employee Stock Purchase Plan during the first six months of FY-12. Accounts receivable increased by $3,235,000 due to increases in revenues and in the timing of receipt of payments; inventories increased by $4,411,000 as a result of the build up for anticipated orders with large international customers and bulk purchases made to receive discounted pricing. In June, the Company closed its purchase of VeroMara for approximately $813,000. In August, the Company completed the purchase of a 128,000 square foot office and warehouse facility in Lexington, Kentucky for $4,950,000. This facility was purchased to accommodate the expansion of the companys animal safety operations. Inflation and changing prices are not expected to have a material effect on operations, as management believes it has and will be successful in offsetting increased input costs with price increases.
Management believes that the Companys existing cash and marketable securities balances at November 30, 2011, along with available borrowings under its credit facility and cash expected to be generated from future operations, will be sufficient to fund activities for the foreseeable future. However, existing cash and borrowing capacity may not be sufficient to meet the Companys cash requirements to commercialize products currently under development or its plans to acquire other organizations, technologies or products that fit within the Companys mission statement. Accordingly, the Company may choose to issue equity securities or enter into other financing arrangements for a portion of its future financing needs.
12
PART I FINANCIAL INFORMATION
Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
The Company has interest rate and foreign exchange rate risk exposure and no long-term fixed rate investments or borrowings. Primary interest rate risk is due to potential fluctuations of exposure to interest rates for variable rate borrowings.
Foreign exchange risk exposure arises because the Company markets and sells its products throughout the world. The Company also could be affected by weak economic conditions in foreign markets that could reduce demand for its products. Additionally, revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. Dollar. The Companys operating results are primarily exposed to changes in exchange rates between the U.S. Dollar, the British Pound Sterling and the Euro. When the U.S. Dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. Dollar strengthens, the opposite situation occurs. Additionally, previously recognized revenues in the course of collection can be affected positively or negatively by changes in exchange rates. The Company uses derivative financial instruments to help manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.
Neogen has assets, liabilities and operations outside of the United States, which are located in Scotland, Brazil and Mexico where the functional currency is the British Pound Sterling, Brazilian Real and Mexican Peso, respectively. The Companys investments in foreign subsidiaries are considered to be long-term.
PART I FINANCIAL INFORMATION
Item 4. | Controls and Procedures |
Evaluation of Disclosure Controls and Procedures
An evaluation of the effectiveness of the design and operation of the Companys disclosure controls and procedures as of November 30, 2011 was carried out under the supervision and with the participation of the Companys management, including the Chairman & Chief Executive Officer and the Vice President & Chief Financial Officer (the Certifying Officers). Based on the evaluation, the Certifying Officers concluded that the Companys disclosure controls and procedures are effective.
Changes in Internal Controls Over Financial Reporting
There was no change to the Companys internal control over financial reporting during the quarter ended November 30, 2011 that materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting.
13
Item 1. | Legal Proceedings |
The Company is subject to certain legal and other proceedings in the normal course of business. In the opinion of management, the outcome of these matters will not have a material effect on its future results of operations or financial position.
Item 6. | Exhibits |
(a) | Exhibit Index |
3(i) | | Restated Articles of Incorporation | ||||
31.1 | | Certification of Chief Executive Officer pursuant to Rule 13a 14 (a). | ||||
31.2 | | Certification of Chief Financial Officer pursuant to Rule 13a 14 (a). | ||||
32 | | Certification pursuant to 18 U.S.C. sections 1350. | ||||
99.1 | | Neogen Corporation 2011 Employee Stock Purchase Plan | ||||
99.2 | | Amended and Restated Neogen Corporation 2007 Stock Option Plan | ||||
101.INS | | XBRL Instance Document | ||||
101.SCH | | XBRL Taxonomy Extension Schema Document | ||||
101.CAL | | XBRL Taxonomy Extension Calculation Linkbase Document | ||||
101.DEF | | XBRL Taxonomy Extension Definition Document | ||||
101.LAB | | XBRL Taxonomy Extension Label Linkbase Document | ||||
101.PRE | | XBRL Taxonomy Extension Presentation Linkbase Document |
Items 1A, 2, 3, 4, and 5 are not applicable or removed or reserved and have been omitted.
14
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NEOGEN CORPORATION (Registrant) | ||||
Dated: December 30, 2011 | ||||
/s/ James L. Herbert | ||||
James L. Herbert Chairman & Chief Executive Officer (Principal Executive Officer) | ||||
Dated: December 30, 2011 | ||||
/s/ Steven J. Quinlan | ||||
Steven J. Quinlan Vice President & Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
15
Exhibit 3.1
C&S-510(10/99)
MICHIGAN DEPARTMENT OF CONSUMER AND INDUSTRY SERVICES CORPORATION, SECURITIES AND LAND DEVELOPMENT BUREAU | ||||
Date Received
FEB 14 2000 |
(FOR BUREAU USE ONLY) | |||
This document is effective on the date (filed, unless a subsequent effective date within 90 days after received date is stated in the document.
|
![]() | |||
RICHARD C LOWE | ||||
1000 MICHIGAN NATIONAL TOWER | ||||
LANSING Ml 48933 | EFFECTIVE DATE: |
Document will be returned to name and address you enter above
If left blank document will be mailed to the registered office.
RESTATED ARTICLES OF INCORPORATION
For use by Domestic Profit Corporations
(Please read information and instructions on last page)
Pursuant to the provisions of Act 284, Public Acts of 1972, the undersigned corporation executes the following Articles:
1. | The present name of the corporation is: Neogen Corporation |
2. | The identification number assigned by the Bureau is: 059-092 |
3. | All former names of the corporation are: None |
4. | The date of filing the original Articles of Incorporation was: June 30, 1981 |
The following Restated Articles of incorporation supersede the Articles of Incorporation as amended and shall be the Articles of Incorporation for the corporation:
Article I
The name of the corporation is: Neogen Corporation
Article II
The purpose or purposes for which the corporation is formed are to engage in any activity within the purposes for which corporations may be organized under the Business Corporation Act of Michigan.
Article II
The total authorized shares:
Common Shares: |
20,000,000 | Preferred Shares: | 100,000 | |||
Par Value: |
$0.16 | Par Value: | $1,00 |
A statement of all or any of the relative rights, preferences and limitations of the shares of each class is as follows:
The Preferred Stock shall be issued from time to time in one or more series of such number of shares with such distinctive serial designations and (a) may have such voting powers; (b) may be subject to redemption at such time or times and at such prices; (c) may be entitled to receive dividends (which may be cumulative or non-cumulative) at such rate or rates, on such conditions, and at such times, and payable in preference to, or in such relation to, the dividends payable on any other class or clases or series of stock; (d) may have such rights upon the dissolution of or upon any distribution of the asets of, the Company; (e) may be convertible into, or exchangeable for, shares of any other class or classes or of any other series of the same or any other class or classes of stock of the Company, at such price or prices or at such rates of exchange, and with such adjustments; and (f) may have such other relative participation, optional or other special rights, preferences, qualifications, limitations, or restrictions thereof, all as shall hereafter be stated and expressed in the resolution or resolutions providing for the issue of each such series of Preferred Stock from time to time adopted by the Board of Directors pursuant to the authority so to do which is hereby expressly vested in the Board of Directors.
Article IV
1. | The address of the current registered office is: |
620 Lasher Place, Lansing, Ml 48912 |
2. | The mailing address of the current registered office, if different than above: |
n/a |
3. | The name of the current resident agent is: James L. Herbert, Jr. |
Article V
When a compromise or arrangement or a plan of reorganization of this corporation is proposed between this corporation and its creditors or any class of them or between this corporation and its shareholders or any class of them, a court of equity jurisdiction within the state, on application of this corporation or of a creditor or shareholder thereof, or on application of a receiver appointed for the corporation, may order a meeting of the creditors or class of creditors or of the shareholders or class of shareholders to be affected by the proposed compromise or arrangement or reorganization, to be summoned in such manner as the court directs. If a majority in number representing 3/4 in value of the creditors or class of creditors, or of the shareholders or class of shareholders to be affected by the proposed compromise or arrangement or a reorganization, agree to a compromise or arrangement or a reorganization of this corporation as a consequence of the compromise or arrangement, the compromise or arrangement and the reorganization, if sanctioned by the court to which the application has been made, shall be binding on all the creditors or class of creditors, or on all the shareholders or class of shareholders and also on this corporation.
Article VI
Any action required or permitted to be taken without a meeting of shareholders may be taken without a meeting if a consent in writing, setting forth such action, is signed by each shareholder entitled to vote on the matter and any other shareholder entitled to notice of a meeting (but not to vote thereat) has waived in writing any right to dissent from such action, and such consent and waiver are filed with the minutes of proceedings of the shareholders.
Article VII
A director is not personally liable to the Corporation or its shareholders for money damages for any action taken or any failure to take an action as a director, except liability for any of the following:
(i) | The amount of a financial benefit received by a director to which he or she is not entitled; |
(ii) | Intentional infliction of harm on the Corporation or the shareholders; |
(iii) | A violation of Section 551 of the Michigan Business Corporation Act; or |
(iv) | An intentional criminal act. |
Any repeal or modification of this Article VII by the shareholders of the corporation shall not adversely affect any right or protection of a director of the corporation existing at the time of such repeal or modification.
Article VIII
The number of directors which shall constitute the whole board shall not be less than five nor more than nine. Within these limits, the number of directors shall be determined from time to time by resolution of the Board of Directors. In lieu of electing the whole number of directors annually, the directors shall be divided into three classes designated as Class I, Class II, and Class III, each class to be as nearly equal In number as possible. The term of office of the Class I directors shall expire at the first annual meeting of the shareholders after the date on which this provision first becomes effective. The term of office of the Class II directors shall expire at the second annual meeting of the shareholders after the date on which this provision first becomes effective. The term of office of the Class III directors shall expire at the end of the third annual meeting after this provision first becomes effective. After such classification, each class of directors shall serve a term of three years. The class of directors whose term expires at the time of the shareholders meeting for & given year shall be elected to hold office until the third succeeding annual meeting. Notwithstanding any of the foregoing, each director shall serve until his or her successor is elected and has qualified or until the directors death, retirement, resignation or removal. Should a vacancy occur or be created, any director elected or appointed to fill such vacancy shall serve for the full term of the class in which the vacancy occurs or is created. If the number of directors is changed, any increase or decrease in the number of directors shall be apportioned among the classes so directors in each class remains as nearly equal in number as possible.
5. | COMPLETE SECTION (a) IF THE RESTATED ARTICLES WERE ADOPTED BY THE UNANIMOUS CONSENT OF THE INCORPORATOR(S) BEFORE THE FIRST MEETING OF THE BOARD OF DIRECTORS; OTHERWISE, COMPLETE SECTION (b). DO NOT COMPLETE BOTH. |
a. ____ | These Restated Articles of Incorporation were duly adopted on the day of , in accordance with the provisions of Section 642 of the Act by the unanimous consent of the incorporator(s) before the first meeting of the Board of Directors. |
Signed this ______________ day of ____________________, ___________.
(Signatures of all incorporators; type or print name under each signature)
b. X | These Restated Articles of Incorporation were duly adopted on the 7th day of October, 1999 in accordance with the provisions of Section 642 of the Act and: (check one of the following) |
____ | were duly adopted by the Board of Directors without a vote of the shareholders. These Restated Articles of Incorporation only restate and Integrate and do not further amend the provisions of the Articles of incorporation as heretofore amended and there is no material discrepancy between those provisions and the provisions of these Restated Articles. |
X | were duly adopted by the shareholders. The necessary number of shares as required by statute were voted in favor of these Restated Articles. |
____ | were duly adopted by the written consent of the shareholders having not less than the minimum number of votes required by statute in accordance with Section 407(1) of the Act. Written notice to shareholders who have not consented in writing has been given. (Note: Written consent by less than all of the shareholders is permitted only if such provision appears In the Articles of Incorporation.) |
____ | were duly adopted by the written consent of all the shareholders entitled to vote in accordance with Section 407(2) of the Act |
Signed this 11th day of February, 2000. | ||||||
By | /s/ James L. Herbert | |||||
James L. Herbert, Jr., President | ||||||
EXHIBIT 31.1
13a. CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
NEOGEN CORPORATION AND SUBSIDIARIES
I, James L. Herbert, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended November 30, 2011 of Neogen Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and |
c) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting. |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of registrants board of directors: |
a) | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Dated: December 30, 2011
/s/ James L. Herbert |
James L. Herbert Chairman & Chief Executive Officer (Principal Executive Officer) |
EXHIBIT 31.2
13a. CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
NEOGEN CORPORATION AND SUBSIDIARIES
I, Steven J. Quinlan, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended November 30, 2011 of Neogen Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and |
c) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting. |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of registrants board of directors: |
a) | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Dated: December 30, 2011
/s/ Steven J. Quinlan |
Steven J. Quinlan Vice President & Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
EXHIBIT 32
18 U.S.C. SECTION 1350 CERTIFICATION
NEOGEN CORPORATION
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report on Form 10-Q of Neogen Corporation (the Company) for the period ended November 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James L. Herbert, as Chief Executive Officer of the Company and I, Steven J. Quinlan, as Chief Financial Officer, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | This Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | Information contained in this Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Dated: December 30, 2011
/s/ James. L. Herbert |
James L. Herbert Chairman & Chief Executive Officer (Principal Executive Officer) |
/s/ Steven J. Quinlan |
Steven J. Quinlan Vice President & Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 99.1
NEOGEN CORPORATION
2011 EMPLOYEE STOCK PURCHASE PLAN
1. Purpose.
The purpose of the Neogen Corporation 2011 Employee Stock Purchase Plan is to encourage employee stock ownership by offering employees of Neogen Corporation and its subsidiaries Purchase Rights (as such term is defined in Section 2) to purchase Common Shares at discounted prices and without payment of brokerage costs. By means of this Plan, the Company seeks to retain the services of its employees, to secure and retain the services of new employees, and to provide incentives for such persons to exert maximum efforts for the success of the Company. The Plan is intended to be an employee stock purchase plan as defined in Section 423 of the Code. The provisions of the Plan shall, accordingly, be construed so as to extend and limit the participation in a manner consistent with the requirements of Section 423 of the Code.
2. Certain Definitions.
Board means the Board of Directors of Neogen Corporation and/or any committee of at least two directors to which the Board of Directors has delegated any of its duties under the Plan. The Board of Directors may abolish any such committee at any time and may re-vest in the Board of Directors all or any part of the Boards duties under the Plan.
Code means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.
Common Shares means the common shares, par value $.16 per share, of Neogen Corporation.
Company means Neogen Corporation, a Michigan corporation, and each of the parent corporations or subsidiary corporations of Neogen Corporation (as those terms are defined for purposes of Section 423(b) of the Code) designated by the Board from time to time. As of the date of adoption of this Plan, the subsidiary corporations of Neogen Corporation so designated by the Board are as set forth on Exhibit A hereto.
Custodian means such firm, firms, person and/or persons as the Board shall designate from time to time.
Exercise Date means the last day of an Offering Period, on which date all Participants outstanding Purchase Rights will automatically be exercised.
Fair Market Value means the average of the high and low quoted sale prices of a Common Share reported by NASDAQ or any successor exchange upon which the Common Shares are traded, or, if no Common Shares were traded on that date, on the next preceding day on which there was such a trade, or, if the Common Shares are not traded in The NASDAQ Global Market, Fair Market Value shall be determined by a method determined by the Board in its discretion.
Offering Period shall have the meaning provided in Section 5(b).
Participant means an employee of the Company who is eligible under Section 3 and who has enrolled in the Plan by providing a Participation Form to the Plan Administrator.
Participation Form shall have the meaning provided in Section 4(a).
Plan means this Neogen Corporation 2011 Employee Stock Purchase Plan.
Plan Administrator means the Board or such committee or person so designated by the Board.
Purchase Right means a Participants option to purchase Common Shares that are deemed to be outstanding during a Offering Period. A Purchase Right represents an option as such term is used under Section 423 of the Code.
Total Compensation means wages, salaries and other amounts received from the Company for personal services rendered to the Company as an employee, including amounts paid as commissions, amounts paid as bonuses and any amounts of salary or bonus reduction contributions to any Company plan under Section 401(k) or Section 125 of the Code, but excluding severance pay, ordinary income received upon disposition of Common Shares acquired under this Plan, amounts paid in cash for accrued vacation not taken as of the end of the year, any other contributions paid by the Company under any employee benefit plan of the Company, other non-cash employee benefits provided to employees at Company expense, taxable income resulting from exercises of non-qualified stock options and other taxable benefits income not paid to the employee in cash.
Trading Day refers to a day during which The NASDAQ system is available for trading Common Shares.
Withdrawal Form shall have the meaning provided in Section 9(a).
3. Eligibility.
Participation in the Plan is voluntary. All employees of the Company, including officers and directors who are employees, are eligible to participate in the Plan, after having been an employee for 180 days, except for an employee whose customary employment with the Company as of the beginning of the applicable Offering Period (1) is 20 hours or less per week, or (2) is for not more than 5 months in any calendar year.
2
4. Participation.
(a) Eligible employees become Participants in the Plan by authorizing payroll deductions for that purpose through a form, electronic authorization or other enrollment means provided by the Company (the Participation Form) that is provided to the Plan Administrator no later than five calendar days after the beginning date of an Offering Period, except as provided in Section 4(b). That Participation Form would be effective for payrolls occurring after the beginning of the applicable Offering Period.
(b) An eligible employee who is newly-hired or re-hired by the Company may become a Participant in the Plan during an Offering Period by authorizing payroll deductions for that purpose through a Participation Form that is provided to the Plan Administrator no later than 180 days after his or her date of hire. That Participation Form would be effective for payrolls occurring at least 10 business days after the Company receives the Participation Form.
(c) All employees who participate in the Plan shall have the same rights and privileges under the Plan except for differences which may be mandated by local law and which are consistent with Code Section 423(b)(5). The Company may impose restrictions on eligibility and participation of employees are officers and directors to facilitate compliance with federal or state securities laws or foreign laws.
(d) Notwithstanding any provision of the Plan to the contrary, no employee may participate in the Plan:
(i) if following a grant of Purchase Rights under the Plan, the employee would own, directly or by attribution, stock, Purchase Rights or other stock options to purchase stock representing 3% or more of the total combined voting power or value of all actually issued and outstanding classes of Neogen Corporations stock or stock in any parent or subsidiary corporation (as those terms are defined for purposes of Section 423(b) of the Code) of Neogen Corporation; for purposes of this Section 4(c)(i), the rules of Section 424(d) of the Code shall apply in determining the stock ownership of any employee; or
(ii) to the extent a grant of Purchase Rights under the Plan would permit the employees rights to purchase stock, under all the Code Section 423 employee stock purchase plans of the Company and of any parent or subsidiary corporation (as those terms are defined for purposes of Code Section 423(b)) of the Company, to accrue at a rate exceeding $25,000.00, based on the Fair Market Value of the stock (at the time of grant), for each calendar year in which such Purchase Rights are outstanding.
5. Securities Subject to the Plan and Offering Periods.
(a) The Plan covers an aggregate of 250,000 Common Shares (subject to adjustment as provided in Section 15), which may be authorized but unissued shares or reacquired shares, bought on the open market or otherwise. If any Purchase Right that shall have been granted under the Plan shall expire or terminate for any reason without having been exercised in full, the unpurchased underlying Common Shares shall again become available for purposes of the Plan, unless the Plan shall have been terminated.
3
(b) The first Offering Period (an Offering Period) under the Plan will begin on December 1, 2011 and end on May 31, 2012. Thereafter, for so long as the Plan remains in effect, there will be semi-annual Offering Periods with the following beginning and ending dates:
Semi-Annual Offering Periods
Beginning Date |
Ending Date | |
June 1 |
November 30 | |
December 1 |
May 31 |
6. Payroll Deductions.
(a) In order to purchase Common Shares, an employee must indicate on the Participation Form the contribution amount he or she wishes to authorize the Company to deduct out of the employees Total Compensation. Subject to the limitation specified by Section 423(b) of the Code and Section 4(d) of the Plan, the authorized contribution amount must be an integral percentage amount (i.e., a whole number percentage) ranging from 1% to 10% of such Participants Total Compensation during the Offering Period. The Participation Form will include authorization for the Company to make payroll deductions from the Participants Total Compensation.
(b) To comply with the federal tax laws, a Participant may not be granted Purchase Rights under the Plan or any other Code Section 423 employee stock purchase plan of the Company, or of any parent or subsidiary corporation (as those terms are defined for purposes of Section 423(b) of the Code) of the Company, with respect to more than $25,000.00 worth of Common Shares for any calendar year in which such Purchase Rights to purchase Common Shares are outstanding pursuant to the terms of the Plan. The foregoing $25,000.00 limit is determined according to the Fair Market Value of the Common Shares on the first day (grant date) of the Offering Period. Participants will be notified if these limitations become applicable to them.
(c) The amounts deducted shall be credited to the Participants account under the Plan, but no actual separate account will be established by the Company to hold such amounts. There shall be no interest paid on the balance outstanding in a Participants account, except where required by local law as determined by the Company. The deducted amounts may be commingled with the general assets of the Company and may be used for its general corporate purposes.
4
(d) Payroll deductions begin on the first payday of each Offering Period, and end on the last payday of each Offering Period. Eligible employees may participate in the Plan and purchase shares only by means of payroll deductions. A Participant may not make any separate cash payment into his or her account.
(e) So long as a Participant remains an employee of the Company eligible to participate in the Plan, payroll deductions will continue in effect from Offering Period to Offering Period unless the Participant:
(i) on or before the end of the current Offering Period, elects a different contribution percentage by providing a new Participation Form to the Plan Administrator; such change in contribution percentage will become effective by the beginning of the next Offering Period following the Plan Administrators receipt of the Participants new Participation Form; or
(ii) withdraws in accordance with Section 9.
(f) Unless a Participant elects a different contribution percentage as permitted by Section 6(e)(i) or elects to withdraw prior to 10 business days before the end of the current Offering Period as permitted under Section 9, the Participants payroll deductions will continue throughout the next Offering Period and his or her Purchase Right to purchase Common Shares will be deemed to be fully and automatically exercised on the last day of such Offering Period with respect to payroll deductions made during that period. Notwithstanding the foregoing, the Company may decrease a Participants payroll deductions to 0% at such time during any Offering Period to the extent necessary to comply with Code Section 423(b)(8) and Section 4(d) of the Plan.
7. Purchase Price.
(a) On the first day of each Offering Period, a Participant is deemed to have been granted a Purchase Right to purchase on the last day of the Offering Period as many whole Common Shares as such Participant will be able to purchase with the payroll deductions credited to such Participants account during that Offering Period.
(b) The price at which each Purchase Right to purchase Common Shares may be exercised is the lower of the following (rounded up to the nearest whole cent per Common Share):
(i) 95% % of the Fair Market Value of the Common Shares on the first day of an Offering Period, or if that day is not a Trading Day, then on the first preceding day that is a Trading Day; or
(ii) 95% % of the Fair Market Value of the Common Shares on the last Trading Day of such Offering Period.
(c) The number of shares purchasable by each Participant per Offering Period will be the number of whole Common Shares obtained by dividing the amount collected from the Participant under the Plan for that Offering Period by the purchase price in effect for that Offering Period.
5
8. Exercise of Purchase Right.
(a) Each outstanding Purchase Right will be exercised automatically on the Exercise Date. The exercise of the Purchase Right is to be effected by applying the amount credited to each Participants account as of the Exercise Date to the purchase on the Exercise Date of whole Common Shares at the purchase price in effect for the Offering Period.
(b) Fractional shares will not be issued under the Plan, and any amount remaining in the Participants account after such application (i.e., amounts not sufficient to purchase a whole Common Share) will be held for the purchase of Common Shares in the next Offering Period.
(c) If the number of shares for which Purchase Rights are exercised exceeds the number of shares remaining available in any Offering Period under the Plan, the shares available for sale will be allocated by the Plan Administrator pro rata among the Participants in such Offering Period in proportion to the relative amounts in their accounts, subject to rounding to allocate only whole Common Shares. Any amounts not thereby applied to the purchase of Common Shares under the Plan will be refunded to the Participants after the end of the Offering Period.
9. Withdrawal and Termination of Purchase Rights.
(a) A Participant may withdraw (i.e., terminate his or her payroll deductions) by providing a notice of withdrawal to the Plan Administrator at any time prior to 10 business days before the end of the current Offering Period. Such notice shall be through a form, electronic authorization or other withdrawal means (the Withdrawal Form) provided by the Plan Administrator for that purpose, and shall be effective by the tenth business day after it is received by the Plan Administrator. The Withdrawal Form will permit a Participant to make the following election:
(i) The Participant may elect to stop the Participants payroll deductions under the Plan and use all of the amounts credited to such Participants account to purchase on the Exercise Date whole Common Shares at the purchase price in effect for the Offering Period. If this election is made, the Company shall distribute to such Participant after such Offering Period any such amounts which remain after such purchase on account of being insufficient to purchase a whole Common Share at the applicable purchase price, unless the Participant has re-enrolled in the Plan, in which case such amounts shall be used to purchase Common Shares in the new Offering Period.
6
(ii) The Participant may elect to continue his or her participation in the Plan through the end of the current Offering Period, and thus exercise such Participants outstanding Purchase Rights on the following Exercise Date, but terminate his or her participation in the Plan for subsequent Offering Periods. Payroll deductions for such a Participant will continue until the end of the current Offering Period. If this election is made, the Company shall distribute to such Participant after such Offering Period any amounts which remain in the Participants account after the purchase of Common Shares on the Exercise Date on account of being insufficient to purchase a whole Common Share at the applicable purchase price, unless the Participant has re-enrolled in the Plan, in which case such amounts shall be used to purchase Common Shares in the new Offering Period.
(b) Any Participant who withdraws from the Plan pursuant to Section 9(a) will not be eligible to rejoin the Plan for the Offering Period under way at the time of withdrawal, and will have to re-enroll in the Plan by completing and providing to the Plan Administrator a new Participation Form should such individual wish to resume participation in a subsequent Offering Period.
(c) If a Participant ceases to be an employee of the Company for any reason during an Offering Period, his or her outstanding Purchase Right will immediately terminate, his or her payroll deductions will immediately cease, and all sums previously collected from such Participant during such Offering Period under the terminated Purchase Right will be refunded; provided, however, that if such termination is the result of the Participants death, (1) the outstanding Purchase Right shall terminate only for future Offering Periods, (2) the Participant or the person or persons to whom the Participants rights under the Plan pass by will or by the laws of descent and distribution (the Beneficiary) shall continue as a Participant until the end of the Offering Period in which such death occurs (except that no further payroll deductions shall be made under the Plan), (3) the sums previously collected from such Participant during such Offering Period under the Plan shall not be refunded during the Offering Period, and (4) the Company shall use all of the amounts credited to such Participants account for the purchase on the Exercise Date of whole Common Shares at the purchase price in effect for the Offering Period, and shall distribute to such Participant or the Participants Beneficiary after such Offering Period any such amounts remaining after such purchase. For purposes of this Plan, a Participant receiving short-term disability payments shall not be deemed to have ceased to be an employee of the Company (and such payments shall be deemed to be part of his or her Total Compensation) unless and until he or she becomes eligible to receive long-term disability benefits.
10. Rights as Shareholder.
(a) A Participant is not a shareholder, and does not have any rights of a shareholder, with respect to any Common Shares subject to Purchase Rights under the Plan until the Participant exercises his or her Purchase Right and certificates representing such shares have been issued, and then only with respect to whole Common Shares issued to the Participant or credited to the Participants account. Thus, a Participant will not have a right to any dividend or distribution on those shares made prior to the Exercise Date.
7
(b) The Participant will be entitled to receive, as soon as practicable after the Exercise Date, a stock certificate for the number of whole purchased shares, if the Participant has so elected. The Participant may also elect to have the Custodian hold his or her Common Shares acquired under the Plan. The Custodian may impose upon, or pass through to, the Participant a reasonable fee for withdrawal of Common Shares in the form of stock certificates. It is the responsibility of each Participant to keep his or her address current with the Company through the Plan Administrator and with the Custodian.
11. Sale or Distribution of Common Shares Acquired Under the Plan.
(a) Participants who elect to have the Custodian or a broker-dealer selected by the Company hold the Common Shares they acquire under the Plan may sell those shares only as of the first business day of each calendar quarter and only if the Participant submits a sales request form, electronic authorization or other sales authorization means provided by the Company to the Plan Administrator at least ten business days before the date on which the Participant desires to have the Common Shares sold. Other Participants who elect to receive a certificate for the Common Shares they acquire under the Plan may sell those Common Shares at any time without restriction under the Plan.
(b) Participants and former Participants who elect to have the Custodian or a broker-dealer selected by the Company hold the Common Shares they acquire under the Plan may withdraw those shares and have certificates issued in the Participants name only as of the first business day of each calendar quarter and only if the Participant submits a share withdrawal request form, electronic authorization or other share withdrawal authorization means provided by the Company to the Plan Administrator at least ten business days before the date on which the Participant desires to have the Common Shares withdrawn.
(c) A Participant shall immediately provide information to the Plan Administrator if the Participant transfers any shares purchased through the Plan within two years from the date of grant of the related Purchase Right. Such transfers shall include transfers into street name and dispositions by sale, gift or other manner. The Participant shall disclose the name of the transferee, the manner of the transfer, the date of the transfer, the number of shares involved and the transfer price. By executing the Participation Form, each Participant obligates himself or herself to provide such information to the Plan Administrator.
(d) The Company is authorized to withhold from any payment to be made to a Participant, including any payroll and other payments not related to the Plan, amounts of withholding and other taxes due in connection with any transaction under the Plan or any transaction involving Common Shares acquired under the Plan, and a Participants enrollment in the Plan will be deemed to constitute his or her consent to such withholding.
8
12. Plan Administration.
(a) The Plan shall be administered by the Board.
(b) The Board shall have the plenary power, subject to, and within the limits of, the express provisions of the Plan:
(i) to determine the commencement and termination date of the offering of Common Shares under the Plan;
(ii) to interpret the terms of the Plan and the rights granted under it, establish, amend and revoke rules for the administration of the Plan and correct or reconcile any defect, omission or inconsistency in the Plan;
(iii) to amend the Plan as provided in Section 16; and
(iv) to exercise such powers and to perform such acts as the Board deems necessary or expedient to carry out the purposes of the Plan or to promote the best interests of the Company.
(c) The Board may delegate all or part of its authority to administer the Plan to the Plan Administrator, who may in turn delegate the day-to-day operations of the Plan to the Custodian or any other person or entity the Plan Administrator designates. The Custodian will establish and maintain, as agent for the Participants, accounts for the purpose of holding Common Shares as may be necessary or desirable for the administration of the Plan for those Participants electing to have the Custodian hold the Common Shares they acquire under the Plan.
(d) The Board may waive or modify any requirement that a notice or election be made, provided or filed under the Plan a specified period in advance in an individual case or by adoption of a rule or regulation under the Plan, without the necessity of an amendment to the Plan.
13. Transferability.
(a) Any account maintained by the Custodian for the benefit of a Participant with respect to shares acquired pursuant to the Plan may only be in the name of the Participant.
(b) Neither payroll deductions credited to a Participants account nor any Purchase Rights or other rights to acquire Common Shares under the Plan may be assigned, transferred, pledged or otherwise disposed of by Participants other than by will or the laws of descent and distribution and Purchase Rights may be exercised only by a Participant during the lifetime of a Participant.
9
14. Merger or Liquidation of the Company.
If (1) Neogen Corporation dissolves or is liquidated, (2) Neogen Corporation merges with another entity and the Company is not the surviving entity, (3) more than 50% of the stock of Neogen Corporation is acquired by another entity, (4) all or substantially all of the assets of Neogen Corporation are acquired by another entity, or (5) any other similar transaction occurs, the Board may, in its discretion and without Participant consent, in connection with such transaction, cancel each outstanding Purchase Right and refund all sums previously collected from Participants under the canceled Purchase Rights, or cause each Participant with outstanding Purchase Rights to have his or her outstanding Purchase Rights exercised immediately prior to such transaction and thereby have the balance of his or her account applied to the purchase of Common Shares at the purchase price in effect for the Offering Period, which would be treated as ending with the effective date of such transaction. In the event of a merger in which the Company is the surviving entity, each Participant is entitled to receive, for each share as to which such Participants Purchase Rights are exercised, the securities or property that a holder of one Common Share was entitled to receive upon the merger.
15. Adjustment.
To prevent dilution or enlargement of the rights of Participants under the Plan, appropriate adjustments shall be made in the event any change is made to the Companys outstanding Common Shares (or other securities then subject to the Plan or any Purchase Right) by reason of any stock dividend, stock split, combination of shares, exchange of shares, change in corporate structure, merger, reorganization, recapitalization, dividend in property other than cash, liquidating dividend or other change in the Common Shares effected without the Companys receipt of consideration. Adjustments shall be made to the maximum number and class of securities issuable under the Plan and the number and class of securities and price per share in effect under each outstanding Purchase Right. Any such adjustments will be made by the Board, and its determination of the appropriate adjustments shall be made in its sole discretion. Any adjustments hereunder shall be made by the Board or its delegate, whose determination in that respect shall be final, binding, and conclusive.
16. Amendment and Termination.
The Board may terminate or amend the Plan and any Purchase Rights at any time and from time to time; provided, however, (1) such termination or amendment may not impair any rights and obligations under Purchase Rights previously granted under the Plan without the consent of each of the affected Participants, and (2) any amendment that increases the number of shares reserved for issuance upon exercise of Purchase Rights under the Plan (except pursuant to Section 14 or 15 and any other changes authorized by the Plan to be made by the Board or the Plan Administrator) or changes the eligibility requirements for participation in the Plan, shall be subject to shareholder approval to the extent required by the Code. The Board may, from time to time, designate the parent corporations or subsidiary corporations (as such terms are defined for purposes of Code Section 423(b)) of Neogen Corporation that may participate in the Plan. The
10
Plan expressly contemplates that the Board may amend the Plan in any respect the Board deems necessary or advisable to provide eligible employees with the benefits provided or to be provided under the provisions of the Code and the regulations promulgated under the Code relating to employee stock purchase plans and/or to bring the Plan and/or the Purchase Rights into compliance with those provisions and regulations. If not sooner terminated by the Board or terminated by expiration, the Plan shall terminate at the time Purchase Rights have been exercised with respect to all Common Shares reserved for acquisition under the Plan. Unless sooner terminated, the Plan shall terminate ten years after its Effective Date (as described in Section 17 below). No Purchase Rights may be granted under the Plan after it is terminated.
17. Shareholder Approval.
The Plan is subject to the approval of shareholders of Neogen Corporation within twelve (12) months of October 6, 2011, its Effective Date. Purchase Rights will not be granted or exercised under the Plan if shareholder approval of the Plan is not obtained before October 5, 2012.
18. No Employment Rights.
Participation in the Plan will not impose any obligations upon the Company to continue the employment of a Participant for any specific period and will not affect the right of the Company to terminate a Participants employment at any time, with or without cause.
19. Costs.
Except as set forth in Section 10(b), costs and expenses incurred in the administration of the Plan and the maintenance of accounts with the Custodian will be paid by the Company, to the extent provided in this Section 19. Any brokerage fees and commissions for the purchase of Common Shares under the Plan will be paid by the Company, but any brokerage fees and commissions for the sale of Common Shares acquired under the Plan by a Participant will be borne by such Participant.
20. Reports.
After the close of each Offering Period, each Participant in the Plan will receive a report indicating the amount of the Participants contributions to the Plan during the Offering Period, the amount of the contributions applied to the purchase of Common Shares for the Offering Period, and the purchase price per share in effect for the Offering Period.
11
21. Governing Law.
The validity, construction and effect of the Plan and any rules and regulations relating to the Plan will be determined in accordance with laws of the State of Michigan, without giving effect to principles of conflict of laws, and applicable federal law.
22. Compliance With Legal and Other Requirements.
The Plan, the granting and exercising of Purchase Rights under the Plan, and the obligations of the Company, the Plan Administrator and the Custodian under the Plan will be subject to all applicable federal and state laws, rules, and regulations, and to such approvals by any regulatory or governmental agency as may be required. The Company may, in its discretion, postpone the issuance or delivery of Common Shares upon exercise of Purchase Rights until completion of registration or qualification of such Common Shares or other required action under any federal or state law, rule, or regulation, listing or other required action with respect to any automated quotation system or stock exchange upon which the Common Shares or other Company securities are designated or listed, or compliance with any other contractual obligation of the Company, as the Company may consider appropriate, and may require any Participant to make such representations and furnish such information as it may consider appropriate in connection with the issuance or delivery of Common Shares in compliance with applicable laws, rules, and regulations, designation or listing requirements, or other contractual obligations. If the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Shares under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Shares upon exercise of Purchase Rights unless and until such authority is obtained.
23. Indemnification.
To the extent permitted, the Company shall indemnify and save harmless the Board, Plan Administrator and Custodian members who are officers, directors, shareholders or employees of the Company against any liabilities incurred by them in the exercise and performance of their powers and duties under the Plan.
24. Notices and Agreements.
Any notices or agreements provided for in the Plan shall be given in writing, in a form provided by the Company, and unless specifically provided for in the Plan, shall be deemed effectively given upon receipt or, in the case of notices and agreements delivered by the Company, three days after deposit in the United States mail, postage prepaid.
12
EXHIBIT A
Designated Subsidiaries
Acumedia Manufacturers, Inc.
Hacco, Inc.
Hess & Clark
International Diagnostic Systems
Centrus International, Inc.
Geneseek, Inc.
13
Exhibit 99.2
AMENDED AND RESTATED
NEOGEN CORPORATION 2007 STOCK OPTION PLAN
NEOGEN CORPORATION
1. Definitions: As used herein, the following terms shall have the following meanings:
(a) Code shall mean the Internal Revenue Code of 1986, as amended, and the applicable rules and regulations thereunder.
(b) Committee shall mean, (i) with respect to administration of the Plan regarding Participants who are subject to Section 16(a) and (b) of the Exchange Act, a committee meeting the standards of Rule 16b-3 of the Rules and Regulations under the Exchange Act, or any similar successor rule, appointed by the Board of Directors of the Company to perform any of the functions and duties of the Committee under the Plan, or the Board of Directors as a whole, (ii) with respect to administration of the Plan regarding Participants whose compensation is subject to Section 162(m) of the Code, a committee comprised solely of two or more outside directors (within the meaning of Treasury Regulation Section 1.162-27(e)(3) or any successor regulation or rule) appointed by the Board of Directors of the Company to perform any of the functions and duties of the Committee under the Plan, or the Board of Directors as a whole, and (iii) with respect to administration of the Plan regarding all other Participants, such committee or the Board of Directors of the Company, as described in clauses (i) or (ii), or such other committee or entity appointed by the Board of Directors of the Company to perform any of the functions and duties of the Committee under the Plan.
(c) Common Shares shall mean the Common Shares, $.16 par value, of the Company.
(d) Company shall mean Neogen Corporation, a Michigan corporation, or any successor thereof.
(e) Discretion shall mean the sole discretion of the Committee, with no requirement whatsoever that the Committee follow past practices, act in a manner consistent with past practices, or treat any key employee, director, or consultant in a manner consistent with the treatment afforded other key employees, directors, or consultants with respect to the Plan or otherwise.
(f) Exchange Act shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.
(g) Incentive Option shall mean an option to purchase Common Shares which meets the requirements set forth in the Plan and also is intended to be, and qualifies as, an incentive stock option within the meaning of Section 422 of the Code, as designated in the applicable award agreement.
(h) Nonqualified Option shall mean an option to purchase Common Shares which meets the requirements set forth in the Plan but is not intended to be, or does not qualify as, an incentive stock option within the meaning of the Code.
(i) Participant shall mean any individual covered by Paragraph 11 or designated by the Committee under Paragraph 6 for participation in the Plan.
(j) Plan shall mean this Neogen Corporation 2007 Stock Option Plan, as amended and restated, and as may be further amended from time to time.
(k) Securities Act shall mean the Securities Act of 1933, as amended, and the rules and regulations thereunder.
(l) Subsidiary shall mean any corporation or other entity in which the Company has a direct or indirect ownership interest of 50% or more of the total combined voting power of all classes of outstanding voting equity interests.
(m) Outside Director shall mean any member of the Companys Board of Directors who is not an employee of Neogen Corporation or any of its Subsidiaries.
2. Purpose of Plan: The purpose of the Plan is to provide key employees (including officers), directors, and consultants of the Company and its Subsidiaries with an increased incentive to make significant and extraordinary contributions to the long-term performance and growth of the Company and its Subsidiaries, to join the interests of key employees, directors, and consultants with the interests of the shareholders of the Company, and to facilitate attracting and retaining key employees, directors, and consultants of exceptional ability.
3. Administration: The Plan shall be administered by the Committee. Subject to the provisions of the Plan, the Committee shall determine, from those eligible to be Participants under the Plan, the persons to be granted stock options, the amount of stock to be optioned to each such person, the time such options shall be granted and the terms and conditions of any stock options. Such terms and conditions may, in the Committees Discretion, include, without limitation, provisions providing for termination of the option, the accelerated vesting of any option, forfeiture of the gain on any option exercises or both if the Participant competes with the Company or otherwise acts contrary to the Companys interests, and provisions imposing restrictions, potential forfeiture or both on shares acquired upon exercise of options granted pursuant to this Plan. The Committee may condition any grant on the potential Participants agreement to such terms and conditions.
Subject to the provisions of the Plan, the Committee is authorized to interpret the Plan, to promulgate, amend and rescind rules and regulations relating to the Plan and to make all other determinations necessary or advisable for its administration. Interpretation and construction of any provision of the Plan by the Committee shall, unless otherwise determined by the Board of Directors of the Company, be final and conclusive. A majority of the Committee shall constitute a quorum, and the acts of a majority of the members present at any meeting at which a quorum is present, or acts approved in writing by a majority of the Committee, shall be the acts of the Committee.
4. Indemnification: In addition to such other rights of indemnification as they may have, the members of the Committee shall be indemnified by the Company in connection with any claim, action, suit or proceeding relating to any action taken or failure to act under or in connection with the Plan or any option granted hereunder to the full extent provided for under the Companys articles of incorporation or bylaws with respect to indemnification of directors of the Company.
5. Maximum Number of Shares Subject to Plan: The maximum number of shares with respect to which stock options may be granted under the Plan shall be an aggregate of 2,500,000 Common Shares, which may consist in whole or in part of authorized and unissued or reacquired Common Shares. Unless the Plan shall have been terminated, shares covered by the unexercised portion of canceled, expired or otherwise terminated options under the Plan shall again be available for option and sale, subject, however, in the case of Incentive Options, to any limitations under the Code.
Subject to Paragraph 17, the number and type of shares subject to each outstanding stock option, the option price with respect to outstanding stock options, the aggregate number and type of shares remaining available under the Plan, and the maximum number and type of shares that may be granted to any Participant in any fiscal year of the Company pursuant to Paragraph 6, shall be adjusted by the Committee, as it deems appropriate to reflect such events as stock dividends, stock splits, recapitalizations, mergers, statutory share exchanges or reorganizations of or by the Company; provided that no fractional shares shall be issued pursuant to the Plan, no rights may be granted under the Plan with respect to fractional shares, and any fractional shares resulting from such adjustments shall be eliminated from any outstanding option. Each adjustment under this Paragraph 5 shall be made so that the aggregate exercise price of each Participants outstanding stock options after the adjustment is not less than the aggregate exercise price of such Participants outstanding stock options before the adjustment.
2
6. Participants: Subject to Paragraph 11, the Committee shall determine and designate from time to time, in its Discretion, those key employees (including officers), directors, and consultants of the Company or any Subsidiary to whom options are to be granted and who thereby become Participants under the Plan; provided, however, that (a) Incentive Options shall be granted only to employees (as defined in the Code) of the Company or a subsidiary corporation (as defined in the Section 424(f) of the Code) of the Company, to the extent required by Section 422 of the Code, or any successor provision, and (b) no Participant may be granted stock options to purchase more than 100,000 Common Shares in the aggregate in any fiscal year of the Company, subject to any adjustments provided in the final paragraph of Paragraph 5 and in Paragraph 17. All Common Shares covered by a stock option granted to a Participant shall be counted for purposes of the per-Participant share limitation of item (b) of the proviso in the immediately preceding sentence, regardless of whether the Participant does not acquire the Common Shares due to cancellation, expiration or termination of the stock option or other event.
7. Allotment of Shares: Subject to Paragraph 11, the Committee shall determine and fix the number of Common Shares to be optioned to each Participant; provided that no Incentive Option may be granted under the Plan to any one Participant which would result in the aggregate fair market value, determined as of the date the option is granted, of the underlying stock with respect to which Incentive Options are exercisable for the first time by such individual during any calendar year (under all of such plans of the Company and its parent and Subsidiary corporations) exceeding $100,000. In the event that any option intended to qualify as an Incentive Option shall exceed such limitation, such option shall be treated as a Nonqualified Option. In no event shall the Company or the Committee have any liability to a Participant or any other party if an option (or any part thereof), which is intended to be an Incentive Option, fails to qualify as such.
8. Option Price: Subject to the rules set forth in this Paragraph 8, the Committee, in its Discretion, shall establish the option price at the time any option is granted. Such option price shall not be less than 100% of the fair market value of the stock on the date on which such option is granted; provided that with respect to an Incentive Option granted to an employee who at the time of the grant owns (after applying the attribution rules of Section 424(d) of the Code) more than 10% of the total combined voting stock of the Company or of any parent or Subsidiary, the option price shall not be less than 110% of the fair market value of the stock subject to the Incentive Option on the date such option is granted. Fair market value of a share shall be determined by the Committee and may be determined by using the closing sale price of the Companys stock on any exchange or other market on which the Common Shares shall be traded on the trading day of the option grant or the trading day before the option grant, or if there is no sale on either such date, the last sale price before the option grant. The option price will be subject to adjustment in accordance with the provisions of Paragraphs 5 and 17 of the Plan.
9. Granting and Exercise of Options: The granting of options under the Plan shall be effected in accordance with determinations made by the Committee pursuant to the provisions of the Plan, by the execution of instruments in writing in form approved by the Committee. Such instruments shall constitute binding contracts between the Company and the Participant.
Subject to the terms of the Plan, the Committee, in its Discretion, may grant to Participants Incentive Options, Nonqualified Options or any combination thereof. Each option granted under the Plan shall designate the number of shares covered thereby, if any, with respect to which the option is an Incentive Option and the number of shares covered thereby, if any, with respect to which the option is a Nonqualified Option.
Subject to the terms of the Plan, each option granted under the Plan shall be exercisable at any such time or times or in any such installments as may be determined by the Committee in its Discretion and specified in the agreement or other written document relating to such option. Except as provided in Paragraph 14, options may be exercised only while the Participant is an employee, director, or consultant of the Company or a Subsidiary.
Notwithstanding any other term or provision of this Plan, but subject to the requirements of the Code with respect to Incentive Options that are intended to remain Incentive Options, in connection with a Participant ceasing to be an employee of or a provider of services to the Company or a Subsidiary for any reason, the stock option agreement may provide for the acceleration of, or the Committee may, but is not required to, accelerate, in its Discretion (exercised at the date of the grant of the stock option or after the date of grant), in whole or in part, the time or times or installments with respect to which any option granted under this Plan shall be exercisable in connection with termination of a Participants employment with or provision of services to the Company or a Subsidiary, subject to any restrictions, terms and conditions fixed by the Committee either at the date of the award or at the date it exercises such Discretion, and provided that any acceleration is made within the original term of the option.
3
Successive stock options may be granted to the same Participant, whether or not the option or options previously granted to such Participant remain unexercised. A Participant may exercise any option granted under the Plan, if then exercisable, notwithstanding that options granted to such Participant prior to the option then being exercised remain unexercised.
Notwithstanding the foregoing, no amendment or modification may be made to an outstanding stock option which reduces the option price, either by lowering the option price or by canceling the outstanding option and granting a replacement or substitute option with a lower exercise price, without the approval of Companys shareholders, provided, that, appropriate adjustments may be made to outstanding options pursuant to Paragraph 5.
10. Payment of Option Price: At the time of the exercise in whole or in part of any option granted under this Plan, payment in full in cash, or with the consent of the Committee, in its Discretion, in Common Shares shall be made by the Participant for all shares so purchased. In the Discretion of, and subject to such conditions as may be established by, the Committee, payment of the option price may also be made by the Company retaining from the shares to be delivered upon exercise of the stock option that number of shares having a fair market value on the date of exercise equal to the option price of the number of shares with respect to which the Participant exercises the option. In the Discretion of the Committee, a Participant may exercise an option, if then exercisable, in whole or in part, by delivery to the Company of written notice of the exercise in such form as the Committee may prescribe, accompanied by irrevocable instructions to a stock broker to promptly deliver to the Company full payment for the shares with respect to which the option is exercised from the proceeds of the stock brokers sale of or loan against some or all of the shares. Such payment may also be made in such other manner as the Committee determines is appropriate, in its Discretion. No Participant shall have any of the rights of a shareholder of the Company under any option until the actual issuance of shares to such Participant, and prior to such issuance no adjustment shall be made for dividends, distributions or other rights in respect of such shares, except as provided in Paragraphs 5 and 17.
11. Automatic Stock Options: Notwithstanding other provisions of this Plan and to the extent shares are available for grant under the Plan, Outside Directors shall automatically be granted Non-qualified Stock Options on the terms described in this Paragraph 11.
Each Outside Director of the Corporation shall automatically be granted a Nonqualified Stock Option to purchase 5,000 shares of Common Stock as of the date he or she is first elected or appointed to the Board of Directors. Each Outside Director of the Corporation who is re-elected to the Board of Directors shall automatically be granted a Nonqualified Stock Option to purchase 2,000 shares of Common Stock as of the date of each re-election.
All options granted under this Paragraph 11 shall be exercisable in one-third cumulative annual installments beginning one year after the date of grant, shall, unless terminated earlier pursuant to the terms of this Plan, expire ten years after the date of grant and shall have an option price equal to 100% of the fair market value of the Companys Common Stock on the date of grant.
12. Non-transferability of Options: No option granted under the Plan to a Participant shall be transferable by such Participant otherwise than by will or by the laws of descent and distribution, and each such option shall be exercisable, during the lifetime of the Participant, only by the Participant.
13. Continuance of Employment; No Right to Continued Employment: The Committee may require, in its Discretion, that any Participant under the Plan to whom an option shall be granted shall agree in writing as a condition of the granting of such option to remain in his or her position as an employee, director, or consultant of the Company or a Subsidiary for a designated minimum period from the date of the granting of such option as shall be fixed by the Committee.
Nothing contained in the Plan or in any option granted pursuant to the Plan, nor any action taken by the Committee hereunder, shall confer upon any Participant any right with respect to continuation of employment, or other service by or to the Company or a Subsidiary nor interfere in any way with the right of the Company or a Subsidiary to terminate such persons employment, or other service at any time.
4
14. Termination of Employment; Expiration of Options: Subject to the other provisions of the Plan, including, without limitation, Paragraph 17 and this Paragraph 14, all rights to exercise options shall terminate when a Participant ceases to be an employee, director, or consultant of the Company or a Subsidiary for any cause, except that the Committee may, in its Discretion, permit the exercise of all or any portion of the options granted to such Participant.
(i) for a period not to exceed three months following such termination with respect to Incentive Options that are intended to remain Incentive Options if such termination is not due to death or permanent disability of the Participant,
(ii) for a period not to exceed one year following termination of employment with respect to Incentive Options that are intended to remain Incentive Options if termination of employment is due to the death or permanent disability of the Participant, and
(iii) for a period not to extend beyond the expiration date with respect to Nonqualified Options or Incentive Options that are not intended to remain Incentive Options,
all subject to any restrictions, terms and conditions fixed by the Committee either at the date of the award or at the date it exercises such Discretion. In no event, however, shall an option be exercisable after its expiration date, and, unless the Committee in its Discretion determines otherwise (pursuant to Paragraphs 9 or 17), an option may only be exercised after termination of a Participants employment or other service by or to the Company to the extent exercisable on the date of such termination or to the extent exercisable as a result of the reason for such termination. The Committee may evidence the exercise of its Discretion under this Paragraph 14 in any manner it deems appropriate, including by written resolution or by a written provision in, or written amendment to, the option.
If not sooner terminated, each stock option granted under the Plan shall expire not more than 10 years from the date of the granting thereof; provided that with respect to an Incentive Option granted to an employee who at the time of the grant owns (after applying the attribution rules of Section 424(d) of the Code) more than 10% of the total combined voting stock of the Company or any parent or subsidiary, such option shall expire not more than 5 years after the date of granting thereof.
15. Investment Purpose: If the Committee in its Discretion determines that as a matter of law such procedure is or may be desirable, it may require a Participant, upon any exercise of any option granted under the Plan or any portion thereof and as a condition to the Companys obligation to deliver certificates representing the shares subject to exercise, to execute and deliver to the Company a written statement, in form satisfactory to the Committee, representing and warranting that the Participants purchase of Common Shares upon exercise thereof shall be for such persons own account, for investment and not with a view to the resale or distribution thereof and that any subsequent sale or offer for sale of any such shares shall be made either pursuant to (a) a Registration Statement on an appropriate form under the Securities Act, which Registration Statement has become effective and is current with respect to the shares being offered and sold, or (b) a specific exemption from the registration requirements of the Securities Act, but in claiming such exemption the Participant shall, prior to any offer for sale or sale of such shares, obtain a favorable written opinion from counsel for or approved by the Company as to the availability of such exemption. The Company may endorse an appropriate legend referring to the foregoing restriction upon the certificate or certificates representing any shares issued or transferred to the Participant upon exercise of any option granted under the Plan.
16. Withholding Payments: If upon the exercise of any Nonqualified Option or a disqualifying disposition (within the meaning of Section 422 of the Code) of shares acquired upon exercise of an Incentive Option, there shall be payable by the Company or a Subsidiary any amount for income tax withholding, in the Committees Discretion, either the Participant shall pay such amount to the Company, or the amount of Common Shares delivered by the Company to the Participant shall be appropriately reduced, to reimburse the Company or such Subsidiary for such payment. The Company or any of its Subsidiaries shall have the right to withhold the amount of such taxes from any other sums or property due or to become due from the Company or any of its Subsidiaries to the Participant upon such terms and conditions as the Committee shall prescribe. The Company may also defer issuance of the stock upon exercise of such option until payment by the Participant to the Company of the amount of any such tax. The Committee may, in its Discretion, permit Participants to satisfy such withholding obligations, in whole or in part, by electing to have the amount of Common Shares delivered or deliverable by the Company upon exercise of a stock option appropriately reduced, or by electing to tender Common Shares back to the Company subsequent to exercise of a stock option to reimburse the Company or such Subsidiary for such income tax withholding, subject to such rules and regulations, if any, as the Committee may adopt. The Committee may make such other arrangements with respect to income tax withholding as it shall determine.
5
17. Extraordinary Transactions: In case the Company (i) consolidates with or merges into any other corporation or other entity and is not the continuing or surviving entity of such consolidation or merger, or (ii) permits any other corporation or other entity to consolidate with or merge into the Company and the Company is the continuing or surviving entity but, in connection with such consolidation or merger, the Common Shares are changed into or exchanged for stock or other securities of any other corporation or other entity or cash or any other assets, or (iii) transfers all or substantially all of its properties and assets to any other corporation or other person or entity, or (iv) dissolves or liquidates, or (v) effects a capital reorganization or reclassification in such a way that holders of Common Shares shall be entitled to receive stock, securities, cash or other assets with respect to or in exchange for the Common Shares, then, and in each such case, proper provision shall be made so that, each Participant holding a stock option upon the exercise of such option at any time after the consummation of such consolidation, merger, transfer, dissolution, liquidation, reorganization or reclassification (each transaction, for purposes of this Paragraph 17, being herein called a Transaction), shall be entitled to receive (at the aggregate option price in effect for all Common Shares issuable to the Participant upon such exercise immediately prior to such consummation and as adjusted to the time of such Transaction), in lieu of Common Shares issuable upon such exercise prior to such consummation, the stock and other securities, cash and assets to which such Participant would have been entitled upon such consummation if such Participant had so exercised such stock option in full immediately prior thereto (subject to adjustments subsequent to such Transaction provided for in Paragraph 5).
Notwithstanding anything in the Plan to the contrary, in connection with any Transaction and effective as of a date selected by the Committee, which date shall, in the Committees judgment, be far enough in advance of the Transaction to permit Participants holding stock options to exercise their options and participate in the Transaction as a holder of Common Shares, the Committee, acting in its Discretion without the consent of any Participant, may effect one or more of the following alternatives with respect to all of the outstanding stock options (which alternatives may be made conditional on the occurrence of the applicable Transaction and which may, if permitted by law, vary among individual Participants): (a) accelerate the time at which stock options then outstanding may be exercised so that such stock options may be exercised in full for a limited period of time on or before a specified date fixed by the Committee after which specified date all unexercised stock options and all rights of Participants thereunder shall terminate; (b) accelerate the time at which stock options then outstanding may be exercised so that such stock options may be exercised in full for their then remaining term; or (c) require the mandatory surrender to the Company of outstanding stock options held by such Participants (irrespective of whether such stock options are then exercisable) as of a date, before or not later than sixty days after such Transaction, specified by the Committee, and in such event the Company shall thereupon cancel such stock options and shall pay to each Participant an amount of cash equal to the excess of the fair market value of the aggregate Common Shares subject to such stock option, determined as of the date such Transaction is effective, over the aggregate option price of such shares, less any applicable withholding taxes; provided, however, the Committee shall not select an alternative (unless consented to by the Participant) such that, if a Participant exercised his or her accelerated stock option pursuant to alternative (a) or (b) and participated in the Transaction or received cash pursuant to alternative (c), the alternative would result in the Participants owing any money by virtue of the operation of Section 16(b) of the Exchange Act. If all such alternatives have such a result, the Committee shall, in its Discretion, take such action to put such Participant in as close to the same position as such Participant would have been in had alternative (a), (b) or (c) been selected but without resulting in any payment by such Participant pursuant to Section 16(b) of the Exchange Act. The gross amount payable to a Participant under alternative (c) shall not be greater than the excess of the fair market value of the aggregate Common Shares subject to the Participants canceled stock option(s) determined on the cancellation date over the aggregate exercise price of such stock option(s). Any amount payable to a Participant under alternative (c) shall be paid within 15 days of the later of the date the Transaction is effective or the date of the Companys cancellation of the Participants stock options. Notwithstanding the foregoing, with the consent of affected Participants, each with respect to such Participants option only, the Committee may in lieu of the foregoing make such provision with respect to any Transaction as it deems appropriate.
18. Effectiveness of Plan: This Plan shall be effective on the date the Board of Directors of the Company adopts this Plan, provided that the shareholders of the Company approve the Plan within 12 months after its adoption by the Board of Directors. Options may be granted before shareholder approval of this Plan, but each such option shall be subject to shareholder approval of this Plan. No option granted under this Plan shall be exercisable unless and until this Plan shall have been approved by the Companys shareholders.
6
19. Termination, Duration and Amendments to the Plan: The Plan may be abandoned or terminated at any time by the Board of Directors of the Company. Unless sooner terminated, the Plan shall terminate on the date ten years after the earlier of its adoption by the Board of Directors or its approval by the shareholders of the Company, and no stock options may be granted under the Plan thereafter. The termination of the Plan shall not affect the validity of any option which is outstanding on the date of termination.
For the purpose of conforming to any changes in applicable law or governmental regulations, or for any other lawful purpose, the Board of Directors shall have the right, with or without approval of the shareholders of the Company, to amend or revise the terms of this Plan or any option agreement under this Plan at any time; provided, however, that (i) to the extent required by Section 162(m) of the Code and related regulations, or any successor rule, but only with respect to amendments or revisions affecting Participants whose compensation is subject to Section 162(m) of the Code, and to the extent required by Section 422 of the Code, or any successor section, but only with respect to Incentive Options, no such amendment or revision shall increase the maximum number of shares in the aggregate which are subject to this Plan or which may be granted to any Participant during any fiscal year of the Company (subject, however, to the provisions of Paragraphs 5 and 17) without the approval or ratification of the shareholders of the Company, and (ii) no such amendment or revision shall change the option price (except as contemplated by Paragraphs 5 and 17) or alter or impair any option which shall have been previously granted under this Plan, in a manner adverse to a Participant, without the consent of such Participant.
20. Section 409A of the Code: Notwithstanding any other provision of the Plan, no stock option granted under the Plan shall have any terms or features (including, without limitation, terms or features relating to the time of or events triggering vesting, method of exercise or payment of withholding tax, method of settlement, form and timing of consideration payable in settlement, or deferral or other elections), whether at the time of grant or subsequent to the time of grant, that would cause the stock option to be nonqualified deferred compensation that fails to comply with, or be exempt from, the requirements under Section 409A of the Code and the guidance and regulations issued thereunder. Moreover, notwithstanding any other provision of the Plan, no action may be taken by the Committee or the Board under or in respect of the Plan (including, without limitation, Plan amendments under Paragraph 19 or adjustments under Paragraphs 5 or 17) that would cause the Plan or any stock option granted under the Plan to be a nonqualified deferred compensation plan that fails to comply with the requirements of Section 409A of the Code and the guidance and regulations issued thereunder. Notwithstanding the foregoing, in no event shall the Company or any Committee member be liable for any adverse tax consequences if the Plan or any award shall fail to comply with, or be exempt from, the requirements under Section 409A of the Code and the guidance and regulations issued thereunder.
21. Compensation Recovery Policy: Awards granted under this Plan shall be subject to any compensation recovery policy adopted by the Company as it exists from time to time.
22. Not Benefit Plan Compensation: Payments and other benefits received by a Participant pursuant to the Plan shall not be deemed a part of a Participants compensation for purposes of determining the Participants benefits under any other employee benefit plans or arrangements provided by the Company or any affiliate, except where the Committee expressly provides otherwise in writing.
As adopted by the Board of Directors on October 6, 2011.
7
*\A<<`^+.4&FF$8+UY"4AW
M=MU^)S"L&R794)`R!*#UV="=[@H4!98%!AGQYXM<`X3^V$CR+[,X#ZP^<^,Y
M\!&>N=Y.BBF+/EFP%:5*FJ6YY<@5.$YM&+]8FV$-L1:CD8C7-V-D,H:M5$;L
M66]GHC#EHA'X`L-(&,W)F09%@/!;]GNAB)[!#VUCFO:Q%L@X.9JL^XH]UA;D
M$3H#N^>M*ZR\3F1JX1A._JTRDSXYX+#AR.),,P,X>!BP(/63;4]$25^:I$EI
M(PN0QR<6Y932ZE]96Y&5[7/=@&O+- >!*&Y6[ZD2G7]ACLPC.I&Q$AC(YW)J
MPG9;.\U"[26+V`56D#G%>Q5D;6J>K6:7N4XD$]3L)F2W%,4A4DF'EC5D8\\"
MU_2?>V';P-DN>835]FU\UPUCKA:X*[%!#2,JI%.&^0J7^&(TD9EDB7EO-;N$
M>$C=#5)29*>:H*&B,4E>L8`G1P'`-Y-#D&`
M8),'NG?;=@D.?4+)F,%MP<^K/C./LX%TW`?RY&8#'C_3C@5-[
M)V=V(5%5?3,QZ'1F?O5 <(54HB2,L<4;75S7`4'R1L^'^9%M"-:>DC!IP<%NRDT(
M$J=N&<,\PLK`QA#5DZHMMG*>PVA>_34I%;$)E\#DT@;;`D+#)HI'9$@3I$[9
M78& ,
M>C@?G5OKZ=ZXY)9]_.)LHL:_*ZM'LYT'V&;0SF]70A<_T4U-_P!W-OY)-H"Q
MO-=U4ILA$<_'#3+,,8'`J/M9:9F$5DP:40?I]H+1#3+4Z1/LVUGU;I6DYA(8
MR5%9!(*O@$.46#+&>(1..0P#;\:2Y1MQ6+7$)"`
MWTGA,GMH<=+VBR9S'Z`U;VD-[:HZQ$RRB;TT8U;L%BL)MMF6(1N\$S9NPK;$
M&6H)[5;^X+\9F;9)W-[9S&82\M60%6`.`!.9#K-MI*NQ'KWW%LF.5^!)7N@=
MLTSL^8P2HHD$4O:Q3ZIE:Y+"60:=0HDD852N.+TR,8]>/3P,*VUV^ANKFE5S[K$M1]F0JK*5=
M+F969@6Y0"G;[=@R;8N-32MHA7]C:W3"MFI[65G.7^PJOG4.N>MFVU:TET2?)=!*VER!6IC
M;CDAR;7%H(4(E1/VB\F9**#3&\'
^#!9_PCGNA=JU-[Q>!#P6;[
M)X?4'&<^,_9YSP+F.`X#@.`X#@.`X#@.`X#@.`X$..Q460=?6]8PY\"#IOLZ
M(.?]60TG-\XS_P#8SC@5'SW0*$[?]7_3-'"-;*^NY951_5X^._WO(BYIL+US
M;_T*O6Q0"U,M4%#>HN^URP&IG=C*,-,>"?0'V#S"BP<"""3K:[6J<9*KC5$'
M6MB!&7YLE=;_`%<]6C0C["=?)#&=N+1
ROU\/=<=$5X
M6/:+E%$SN\286R]*]D%W*9